Stephen L. Silvestro

Stephen L. Silvestro (chief executive) discloses dealings in OptimizeRx Corp to SEC (Form 4). In total, 29 filings cover trades dated from 17 May 2021 to 21 August 2026.

The open-market side counts 1 purchase for €49k alongside 1 sale for €465k. The net balance comes to €416k on the selling side. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Outside the open market, there are 10 share grants and 17 option exercises.

On 24 August 2026 came the latest disclosure, a share grant for €11k in OptimizeRx Corp. The clock since the last published purchase (17 August 2022) now reads 1,529 days. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 4 days. For comparison, the SEC allows two business days to file a Form 4. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.